Friday, August 5, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

Development of Bioscavengers for U.S. Army

by Global Biodefense Staff
September 1, 2014

The U.S. Army Medical Research Institute of Chemical Defense (USAMRICD) is seeking services to develop rapidly absorbed and persistent bioscavengers.

Bioscavengers are proteins that react specifically and quickly with organophosphate (OP) chemical agents without causing undesirable side-effects.

Medical chemical mitigation by bioscavengers is a promising means of protection against nerve agent toxicity. Two of the important desirable bioscavenger characteristics include rapid absorption of bioscavengers from an IM dose into the blood stream and persistence of this bioscavenger in the blood.

Under the proposed contract, USAMRICD wants to make use of mouse red blood cell (RBC) epitopes to target bioscavengers to RBCs. Therapeutic proteins delivered in this manner could potentially improve the retention times as great as the native RBC of 120 days. With such treatment it would be possible to retain higher effective concentrations of the therapeutic proteins and reduce or eliminate multiple dosing.

The means of the work will be to create an immunized domain Nb library by immunizing a llama or camel with the target protein ECD and mouse RBCs. RNA is extracted from splenocytes (or lymphocytes) and by PCR methods amplified and the VHH regions cloned into filamentous bacteriophages to produce a protein display library. The library is initially screened to isolate binders. The select library is then screened to identify high-affinity single domain binders. The identified high-affinity Nb genes will then be sequenced.

Further details are available under Solicitation Number: W81XWH-14-T-0461. The response deadline is September 8, 2014.

Tags: Bioscavengers

Related Posts

Influenza Transmission Spikes During Social Gatherings
Medical Countermeasures

New Universal Flu Vaccine Offers Broad Protection Against Influenza A Virus Infections

July 17, 2022
Adverse Events After Simultaneous COVID-19 mRNA Booster, Flu Vaccination
Medical Countermeasures

Adverse Events After Simultaneous COVID-19 mRNA Booster, Flu Vaccination

July 16, 2022
US Starts Clinical Trial for mRNA Nipah Virus Vaccine
Medical Countermeasures

US Starts Clinical Trial for mRNA Nipah Virus Vaccine

July 11, 2022
Targeting Poxviruses with Messenger RNA Technology
Medical Countermeasures

Targeting Poxviruses with Messenger RNA Technology

July 11, 2022
Load More

Latest News

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast

July 27, 2022
Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids

Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids

July 17, 2022
Influenza Transmission Spikes During Social Gatherings

New Universal Flu Vaccine Offers Broad Protection Against Influenza A Virus Infections

July 17, 2022
Long COVID: National Academies’ Panel Examines Long-Term Health Effects of COVID-19

Long COVID: National Academies’ Panel Examines Long-Term Health Effects of COVID-19

July 17, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy